Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma

Ellen R. Gaynor, Geoffrey R. Weiss, Kim A. Margolin, Frederick R. Aronson, Mario Sznol, Paul Demchak, Kathleen M. Grima, Richard I. Fisher, David H. Boldt, James H. Doroshow, Michael H. Bar, Michael J. Hawkins, James W. Mier, Geralyn Caliendo

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

The current study was undertaken to determine the maximum tolerated dose of recombinant interleukin-2 (rIL-2) that could be administered as a continuous infusion in conjunction with autologous lymphokine-activated killer (LAK) cells. All 55 patients in this study received a priming dose of rIL-2 of 1.0 mg/m2 per day given as a continuous infusion over 4.5 days. Patients later received (days 11-16) one of three doses of rIL-2 per day (1.0, 1.25, or 1.50 mg/m2) in conjunction with LAK cells given on days 11, 12, and 14. Because of unacceptable toxicity occurring early in the LAK cell phase of therapy at the rIL-2 dose level of 1.50 mg/m2, we concluded that the maximum tolerated dose of rIL-2 given as a continuous infusion with LAK cells is 1.25 mg/m2 per day. [J Natl Cancer Inst 82: 1397-1402, 1990]

Original languageEnglish (US)
Pages (from-to)1397-1402
Number of pages6
JournalJournal of the National Cancer Institute
Volume82
Issue number17
DOIs
StatePublished - Sep 5 1990

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma'. Together they form a unique fingerprint.

Cite this